NR3C2 and breast carcinoma: Interestingly the AR, ER and MR have been shown to inhibit apoptosis in skeletal cells, breast cancer cells, neuronal cells and/or cardiomyocytes, when activated by their receptor-selective agonists, an effect that is most likely cell-specific [102], [103]–[105].